CSL Ltd., the only influenza-vaccine maker in the Southern Hemisphere, posted first-half profit that rose more than analysts estimated on sales of swine flu shots.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.